Altair Medical is rebranding to PneumoWave.
In another step towards commercial launch of the company's platform, a multi-centre program of clinical trials is currently underway in various academic and healthcare institutions.
Altair Medical was founded in 2018 with the purpose of developing remote monitoring technology for patients with acute and chronic respiratory conditions.
The platform aims to provide patients, clinicians and researchers with real-time physiological data and patient-centric biomarkers to predict, monitor and alert to respiratory-adverse events in hospitals and at home.
Having been identified as a device offering advantages over existing alternatives, PneumoWave has been awarded US Food & Drug Administration Breakthrough Medical Device designation.
Chief executive Dr Bruce Henderson explained: “We’ve reached the stage in our development where our growing team, clinical trial and leading academic partners know us as PneumoWave.
“The name reflects our core technology of remote respiratory monitoring, advanced algorithms and AI being used to diagnose underlying health events in real time.
“This allows those using the platform to provide therapeutic interventions and alerts to prevent unnecessary deaths and improve patient outcomes.”
PneumoWave chair Jonathan Guthrie added: “Imminently we’re embarking on our next fundraise and with commercial launch coming ever closer, we feel it’s time to bring clarity to the market with our new name.
“We thank our investors who backed us as Altair Medical through our £2.25m pre-Series A funding, and look forward to our next exciting growth period as PneumoWave.”
PneumoWave currently employs 16 people in the UK and US.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
